Skip to main content

Table 1 Characteristics of Cases and Controls

From: Relation of therapies for ankylosing spondylitis and psoriatic arthritis to risk of myocardial infarction: a nested case control study

 

AS

P-value

PsA

P-value

MI Cases

Controls

MI Cases

Controls

Subjects, n

237

894

 

404

1596

 

Female, n (%)

110 (46.4%)

406 (45.4%)

0.7836

167 (41.3%)

660 (41.4%)

0.9951

Age, mean +/− SD

63.0 +/−  11.3

62.8 +/− 11.0

0.7100

61.5 + −  11.2

61.4 + −  11.2

0.8300

Chronic kidney disease, n (%)

13 (5.5%)

36 (4.0%)

0.3269

22 (5.4%)

45 (2.8%)

0.0088

Diabetes, n (%)

62 (26.2%)

191 (21.4%)

0.1152

138 (34.2%)

329 (20.6%)

< 0.0001

Ischemic heart disease, n (%)

66 (27.8%)

131 (14.7%)

< 0.0001

100 (24.8%)

209 (13.1%)

< 0.0001

Liver disease, n (%)

< 11a (< 5.0%)

22 (2.5%)

NSa

20 (5.0%)

58 (3.6%)

0.2221

Peptic ulcer disease, n (%)

58 (24.5%)

233 (26.1%)

0.6186

71 (17.6%)

297 (18.6%)

0.6316

Psoriasis, n (%)

42 (17.7%)

173 (19.4%)

0.5697

259 (64.1%)

1073 (67.2%)

0.2347

Rheumatoid arthritis, n (%)

76 (32.1%)

237 (26.5%)

0.0891

99 (24.5%)

340 (21.3%)

0.1649

Body mass index > 30 kg/m2), n (%)

33 (13.9%)

104 (11.6%)

0.3365

75 (18.6%)

201 (12.6%)

0.0019

Statin use, n (%)

95 (40.1%)

308 (34.5%)

0.1075

147 (36.4%)

565 (35.4%)

0.7118

Smoking status, n (%)

28 (11.8%)

54 (6.0%)

0.0023

41 (10.1%)

76 (4.8%)

< 0.0001

Rheumatology visit in year prior to diagnosis, n (%)

103 (43.5%)

406 (45.4%)

0.8200

214 (53.0%)

911 (57.1%)

0.0200

ESR/CRP ordered in year prior to diagnosis, n (%)

95 (40.1%)

349 (39.0%)

0.7693

175 (43.3%)

651 (40.8%)

0.3567

  1. P values were labeled as non-significant, or NS, when p was > 0.05 and was unable to be reported due to the risk of calculating small numbers of subjects (< 11)
  2. SD Standard deviation, ESR Erythrocyte sedimentation rate, CRP c-reactive protein, NS Non-significant
  3. aCounts under 11 subjects were not reported to prevent inadvertent subject identification